INS and diabetes mellitus: In this context, our findings focusing on long-acting insulin (which constitutes a large proportion of insulin prescriptions and expenditures in the US [20]) generate a hypothesis that physician–industry financial relationship may increase the overall costs of long-acting insulin for patients with diabetes, which works against the national effort to reduce the patients’ financial burden of using insulin.